Endocrine Abstracts

Background: A specific self-administered health-related quality of life questionnaire for sarcopenia, the sarcopenia and Quality of life (SarQol®) has been recently developed. The questionnaire is composed of 55 items and organized into seven domains of quality of life. The Pasieka Quality of life questionnaire (PAS-Qol) is a specific self-administered quality of life questionnaire that has been developed for patients with primary hyperparathyroidism. The questionnaire has been developed as an assessment tool to find out how primary hyperparathyroidism affected patients’ lifestyle and wellbeing. Many of these symptoms develop insidiously and are not easily recognized. If you have primary hyperparathyroidism and your score is over 200 then you are likely to be symptomatic and affected by the disorder. Sarcopenia and low quality of life are widely found among patients suffering from primary hyperparathyroidism.Aim This study aims to verify whether risk of sarcopenia can predict quality of life in patients with primary hyperparathyroidism.

Methods: The study included both men and women diagnosed with primary hyperparathyroidism and community-dwelling adults with no known hyperparathyroidism disorder. Both groups were assessed with the SarQol questionnaire, and the hyperparathyroidism group was also assessed with the PAS-Qol questionnaire.

Results: Of the 100 included individuals 80% were women with a mean age of 63.8years. Increased age is associated with a lower quality of life (<−1.160, P<0.001) in the community-dwelling adults, and gender, with females as the reference is also a significant negative predictor (−11.323, P=.010).Neither age (B=4.845, P=.219) nor gender (B=−37.816, P=0.685) significantly predicted quality of life in hyperparathyroidism group using the PAS-Qol scale. The mean overall scores of the SarQol scale for patients of the normal group was 72.6 (S.D.=14.9) and for the hyperparathyroidism group 63.7 (S.D.=15.1). There was a statistically significant difference (P=0.006), suggesting that individuals with hyperparathyroidism generally had lower quality of life scores compared to those without the condition. Between the quality-of-life scores as assessed by the SarQol scale and the PAS-Qol scale there is a significant negative correlation suggesting that as the SarQol score increases PAS-Qol score tends to decline in primary hyperparathyroidism (negative correlation −0.444**, P=0.001).

Conclusion: The study highlights the potential interconnectedness between these two conditions, sarcopenia and primary hyperparathyroidism, and their impact on patients’ overall well-being. The study emphasizes the need for comprehensive management strategies addressing both sarcopenia and hyperparathyroidism to enhance patients’ quality of life.